U.S. Markets open in 7 hrs 15 mins

Sol-Gel Technologies Ltd. (SLGL)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
12.10+0.05 (+0.41%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close12.05
Open12.02
Bid0.00 x 900
Ask0.00 x 800
Day's Range11.92 - 12.10
52 Week Range7.00 - 16.69
Volume11,471
Avg. Volume41,612
Market Cap278.642M
Beta (5Y Monthly)1.37
PE Ratio (TTM)N/A
EPS (TTM)-1.14
Earnings DateAug 04, 2021 - Aug 09, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est19.25
  • Sol-Gel Technologies to Report Second Quarter 2021 Financial Results on August 4th, 2021
    GlobeNewswire

    Sol-Gel Technologies to Report Second Quarter 2021 Financial Results on August 4th, 2021

    NESS ZIONA, Israel, July 20, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, will report second quarter 2021 financial results on Wednesday, August 4, 2021 at 7:05 AM ET. About Sol-Gel Technologies Sol-Gel is a clinical-stage dermatology company focused on identifying, developing and commercializing branded a

  • Sol-Gel Announces Pipeline Update and Future Development Plans
    GlobeNewswire

    Sol-Gel Announces Pipeline Update and Future Development Plans

    Sol-Gel investigational SGT-510 was found to be more effective than roflumilast cream, 0.3%, in a human xenograft psoriasis animal modelSol-Gel is developing tapinarof cream, 1%, aiming to offer product formulation innovations and increased affordability for patients compared to the brand expected to be launchedOur proof-of-concept study for SGT-210 (erlotinib gel) in palmoplantar keratoderma patients has been completed and indicated a possible modest improvementSol-Gel to host Conference Call t

  • Sol-Gel Technologies and Galderma Announce Exclusive Licenses for the Commercialization of EPSOLAY® and TWYNEO® in the United States
    Business Wire

    Sol-Gel Technologies and Galderma Announce Exclusive Licenses for the Commercialization of EPSOLAY® and TWYNEO® in the United States

    NESS ZIONA, Israel & LAUSANNE, Switzerland, June 28, 2021--Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company, and Galderma, the world’s largest independent dermatology company, today announced they have signed two exclusive 5-year license agreements for the commercialization of EPSOLAY® and TWYNEO® in the United States.